Centre to require pharmas to distinguish biologics from synthetics
The government's proposed regulatory intervention aims to address ambiguity around drugs, such as semaglutide, that can be produced chemically as well as biologically.
The Union government in India is set to introduce new regulations that will force pharmaceutical companies to differentiate between biological medicines, also known as biologics, and synthetic drugs when applying for licenses and on product packaging, according to sources familiar with the matter. These modifications will be implemented through amendments to the Drugs Rules, 1945, a government official close to the discussions revealed to Mint, a leading news outlet based in New Delhi.
The changes aim to ensure transparency and clarity for consumers and healthcare providers when it comes to understanding the nature of the pharmaceutical products they are using.
Written by urgent.news from Live Mint's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
